Quantcast

Latest B-cell chronic lymphocytic leukemia Stories

2014-05-14 23:05:42

RnRMarketResearch.com adds “EpiCast Report Amyotrophic Lateral Sclerosis & Chronic Lymphocytic Leukemia – Epidemiology Forecast to 2023” to its store. Develop business strategies by understanding the trends shaping and driving the global ALS & CLL market. Dallas, Texas (PRWEB) May 14, 2014 EpiCast Report: Amyotrophic Lateral Sclerosis – Epidemiology Forecast to 2023 Amyotrophic lateral sclerosis (ALS), often referred to as “Lou Gehrig’s Disease,” is a rare, but...

2014-05-14 16:29:31

- Research in hematological malignancies features: ibrutinib (IMBRUVICA®), siltuximab (SYLVANT(TM)) and daratumumab; research in solid tumors features: abiraterone acetate (ZYTIGA®), ARN-509, trabectedin and JNJ-42756493 RARITAN, N.J., May 14, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May...

2014-05-07 16:27:52

Having successfully Pioneered Robotic Surgery, Robert "Bob" Duggan Is Giving Hope to Cancer Patients Through His Innovative Biotech Company SUNNYVALE, Calif., May 7, 2014 /PRNewswire-iReach/ -- Robert Duggan is at it again, this time leading the way with innovation in the field of cancer treatment. Duggan is CEO of Pharmacyclics Inc., a biotech company based in Sunnyvale, California. He and his team are experiencing major success in treating patients with Mantle Cell Lymphoma (MCL)...

2014-05-02 08:24:57

First full quarter after launch of IMBRUVICA(TM) net product revenue of $56.2 million SUNNYVALE, Calif., May 2, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended March 31, 2014. Financial Results for the Quarter Ended March 31, 2014 GAAP and Non-GAAP net income (loss) Non-GAAP net income reported for the quarter ended March 31, 2014 was $31.3 million, or $0.40 net income per diluted share,...

2014-04-23 08:31:41

- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative...

2014-04-22 08:32:53

FLINT, Mich., April 22, 2014 /PRNewswire-iReach/ -- The US Food and Drug Administration has announced the expanded approval of Arzerra(®) (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra(®) was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra(®). In the clinical trials results were evaluated based on...

2014-04-21 12:27:29

SUNNYVALE, Calif., April 21, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that data from the Phase III PCYC-1112 (RESONATE(TM)) study of single agent IMBRUVICA(TM) (ibrutinib) vs. ofatumumab, an established therapy in relapsed refractory CLL, as well as data from an Independent Efficacy Evaluation of IMBRUVICA after three years of follow-up, will be presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago, Illinois May 30 - June...

2014-04-17 16:27:38

LONDON, April 17, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra(®) (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered...

2014-04-13 23:01:08

Transparency Market Research Report Added "Blood Disease Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database. Browse Full Report: http://www.transparencymarketresearch.com/blood-disease-treatment-drugs.html. Albany, New York, USA (PRWEB) April 13, 2014 Blood comprises of red blood cells, white blood cells, plasma and platelets. Sometimes, people might be affected with different types of blood disorders and...

2014-04-10 12:24:44

Emerging Therapies are Not Expected to Offer Improvements in Safety and Tolerability Attributes, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed U.S. and European hematological oncologists' prescribing decisions for relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related